Professor Peter Lane


Professor Peter Lane is a clinical immunologist whose research focusses on the cellular and molecular mechanisms that modulate the development of CD4 effector and memory T cells.

Professor of Clinical Immunology, Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham. 


UoB profile

LinkedIn profile

Background and Research focus

Professor Peter Lane is a clinical immunologist in the Institute of Immunology and Immunotherapy whose research focusses on the cellular and molecular mechanisms that modulate the development of CD4 effector and memory T cells. A large proportion of this research has been carried out in collaboration with Prof Graham Anderson. CD4 T-cells play a crucial role regulating both protective but also pathogenic immune responses. Peter and his team are interested in understanding the development and function of thymic medullary epithelial cells. In particular, their research has revealed a critical role for lymphoid tissue inducer cells (LTIs) in establishing intrathymic medullary microenvironments that regulate central tolerance. Importantly, they have also demonstrated that LTIs play a key role in the generation of memory CD4+ T-cells, and are presently studying the function of LTIs in tolerance and immunity. Professor Lane’s group has also revealed a key role of TNF receptors, OX40 and CD30, in the survival of memory CD4+ T-cells within the gut lamina propria. This study is particularly relevant for the modulation OX40 and CD30 signalling pathways in intestinal inflammatory diseases.   Currently, his team is focused on investigating the potential of manipulating the TNF receptor pathway in combination with checkpoint blockade to enhance anti-tumour immune responses. Indeed, clinical trials performed in the context of melanoma and lung cancer have demonstrated that antibody blockade of inhibitory receptors such as CTLA-4 and PD-1/PD-L1 can unleash potent and therapeutically significant effector responses from tumour infiltrating lymphocytes. In this vein, Professor Lane’s research could identify new checkpoint blockade strategies and targets that are both safe, and effective at promoting strong anti-tumour responses.


CD4 effector and memory T cells; CD4 T cell biology; T cell tolerance and Immunity; intestinal inflammatory disease; lymphoid tissue inducer cells; mouse models; checkpoint blockade; TNF receptor.

Other activities

Peter has received funding in the form of programme grants from the MRC and the Wellcome Trust Fund.  He also serves as a Theme lead in the MRC Centre for Immune regulation which provides a coherent focus for immunology research supported by cutting-edge technologies. The overall aim of the research focused in the Centre is to gain an in-depth understanding of how the the immune system is regulated to allow the development of novel strategies for combating autoimmune disease and infection. Peter also assesses patients with immunodeficiency, allergy and autoimmunity at the UHB and Heartlands Trust. Alongside his research and clinical commitments, Peter has made substantial contributions to organization and teaching on various taught programmes at the University of Birmingham. In particular, he leads the Immunology modules on the MBChB (Year 3) and intercalated BMedSc courses. Finally he regularly reviews grants for the MRC, ARUK and Wellcome Trust.


Lane PJ, McConnell FM, Anderson G, Nawaf MG, Gaspal FM, Withers DR. Evolving Strategies for Cancer and Autoimmunity: Back to the Future. Front Immunol. 2014 Apr 14;5:154.

Nakamura K, White AJ, Parnell SM, Lane PJ, Jenkinson EJ, Jenkinson WE, Anderson G. Differential requirement for CCR4 in the maintenance but not establishment of the invariant V?5(+) dendritic epidermal T-cell pool. PLoS One.  2013 Sep 12;8(9):e74019.

Anderson G, Baik S, Cowan JE, Holland AM, McCarthy NI, Nakamura K, Parnell SM, White AJ, Lane PJ, Jenkinson EJ, Jenkinson WE. Mechanisms of thymus medulla development and function. Curr Top Microbiol Immunol. 2014;373:19-47.

Cowan JE, Parnell SM, Nakamura K, Caamano JH, Lane PJ, Jenkinson EJ, Jenkinson WE, Anderson G. The thymic medulla is required for Foxp3+ regulatory but not conventional CD4+ thymocyte development. J Exp Med. 2013 Apr 8;210(4):675-81.

Baik S, Jenkinson EJ, Lane PJ, Anderson G, Jenkinson WE. Generation of both cortical and Aire(+) medullary thymic epithelial compartments from CD205(+) progenitors. Eur J Immunol. 2013 Mar;43(3):589-94. doi: 10.1002/eji.201243209. Epub 2013 Feb 11.

Desanti GE, Cowan JE, Baik S, Parnell SM, White AJ, Penninger JM, Lane PJ, Jenkinson EJ, Jenkinson WE, Anderson G. Developmentally regulated availability of RANKL and CD40 ligand reveals distinct mechanisms of fetal and adult cross-talk in the thymus medulla. J Immunol. 2012 Dec 15;189(12):5519-26.

Roberts NA, White AJ, Jenkinson WE, Turchinovich G, Nakamura K, Withers DR, McConnell FM, Desanti GE, Benezech C, Parnell SM, Cunningham AF, Paolino M, Penninger JM, Simon AK, Nitta T, Ohigashi I, Takahama Y, Caamano JH, Hayday AC, Lane PJ, Jenkinson EJ, Anderson G. Rank signaling links the development of invariant ?? T cell progenitors and Aire(+) medullary epithelium. Immunity. 2012 Mar 23;36(3):427-37.

Withers DR, Gaspal FM, Bekiaris V, McConnell FM, Kim M, Anderson G, Lane PJ.  OX40 and CD30 signals in CD4(+) T-cell effector and memory function: a distinct role for lymphoid tissue inducer cells in maintaining CD4(+) T-cell memory but not effector function. Immunol Rev. 2011 Nov;244(1):134-48.

Gaspal F, Withers D, Saini M, Bekiaris V, McConnell FM, White A, Khan M, Yagita H, Walker LS, Anderson G, Lane PJ. Abrogation of CD30 and OX40 signals prevents autoimmune disease in FoxP3-deficient mice. J Exp Med. 2011 Aug 1;208(8):1579-84.

Lane, P.J.L., F.M. McConnell, D. Withers, F. Gaspal, M. Saini, and G. Anderson, editors. 2010. Lymphoid Tissue Inducer Cells and the Evolution of CD4 Dependent High-Affinity Antibody Responses. Academic Press, Burlington. 159-176 binding of a human gamma delta T cell antigen receptor to endothelial protein C receptor. Nat Immunol  13(9): 872-9.